Microangiopathies, in particular diabetic retinopathy. Clinical signs of chronic venous insufficiency in the lower limbs (pain, cramps, paresthesia, oedema, stasis dermatosis), as adjuvant in superficial thrombophlebitis. Haemorrhoidal syndrome, microcirculation disorders of arteriovenous origin.
Calcium Dobesilate is a vasoactive drug that presumes effects on endothelial integrity, capillary permeability and blood viscosity. It decreases capillary hyperpermeability, decreases platelet aggregation (clotting- adhesion of platelets) and reduces the serum viscosity, which improves blood circulation and blood supply to tissues and organs.
Generally 500 to 1000mg ? 1 capsule once or twice a day - to be taken with the main meals. Treatment duration, which is generally between a few weeks and several months, depends on the disease and its evolution. Dosage should be adapted individually according to the severity of the case.
Hypersensitivity towards calcium dobesilate
Nausea, diarrhoea, vomiting.,pruritus,rash.
Pregnancy category C: studies in pregnant women or animals are not available. As it is not known whether calcium dobesilate crosses the placental barrier in humans, the drug should only be administered if the potential benefit justifies the potential risk to the foetus. Calcium dobesilate enters the maternal milk in very low quantities (0,4 ?g/ml after intake of 3x500mg). As a precaution, either the treatment or the breastfeeding should be stopped.
The clinical signs of a possible over dosage are not known.
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)